Diaceutics PLC
The Cavendish View
Diaceutics (Not covered) operates within the precision medicine market, facilitating improved access to patient-appropriate therapies, driving improved market penetration for its biopharma customers and therefore supporting better treatment outcomes. Meeting management would provide an opportunity to be updated on market penetration and the increasing focus on developing recurring revenue streams.
CHRIS DONNELLAN
Research Director
End-to-end therapy commercialization for the precision era
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for precision medicines through data analytics, and scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.
Attending from Diaceutics PLC
Ryan Keeling
CEO
Company descriptions are drawn from information published by each company and have not been independently verified by Cavendish. They are for information only, are not investment research, advice or a recommendation, and do not constitute an offer or invitation to buy or sell any security. Information is correct as at 10th September 2026 and will not be updated. Investors should refer to each company's own published announcements and accounts. Cavendish acts as adviser or broker to certain of the companies featured.